宫颈癌前瞻性成像与新辅助治疗(PRICE)研究:超声评估局部晚期宫颈癌患者同步放化疗后根治性手术前残留肿瘤的作用
该研究纳入88例局部晚期宫颈癌(IB2-IVA期)患者,在新辅助放化疗结束后5周行二维超声、三维能量多普勒及超声造影检查,以病理为参考标准评估残留病变。病理完全缓解40例(45.5%),部分缓解48例(54.5%)。二维灰阶超声检测残留病变灵敏度64.6%、特异度65%;彩色多普勒灵敏度87.1%、特异度21.4%;预测直径至少6 mm残留病变的最佳曲线下面积为0.817。
要点
- 灰阶与彩色多普勒超声检测新辅助放化疗后残留病变的诊断性能较低。
- 彩色多普勒检测残留病变灵敏度87.1%,特异度仅21.4%。
- 预测至少6 mm残留病变曲线下面积0.817,以12 mm为界值灵敏度95%、特异度70.6%。
核心结论
- 灰阶和彩色多普勒超声在新辅助放化疗后检测局部晚期宫颈癌残留病变的诊断性能较低。
- 检测宏观(≥6 mm)残留病变时诊断性能最佳。
研究设计与样本
- 2010年10月至2014年6月筛查108例组织学确诊的局部晚期宫颈癌IB2-IVA期患者,最终纳入88例进行分析。
- 在新辅助放化疗结束后5周评估二维超声参数、三维能量多普勒及超声造影参数,以病理为参考标准。
- 病理反应定义为完全缓解(治疗后无任何残留肿瘤)或部分缓解(病理检查见微观和/或宏观残留肿瘤)。
主要发现
- 病理完全缓解40例(45.5%),部分缓解48例(54.5%)。
- 二维灰阶超声检测病理证实的残留病变灵敏度64.6%、特异度65%。
- 彩色多普勒在灰阶成像可见病灶者中检测病理证实的残留病变灵敏度87.1%、特异度21.4%。
- 预测直径至少6 mm病理残留病变的最佳曲线下面积为0.817,以二维灰阶超声最大肿瘤直径12 mm为界值,灵敏度95%、特异度70.6%。
- 三维血管指数及超声造影参数在组织学完全缓解与部分缓解患者间无显著差异。
关键数值与推荐
- 二维灰阶超声检测残留病变:灵敏度64.6%,特异度65%。
- 彩色多普勒检测残留病变:灵敏度87.1%,特异度21.4%。
- 预测至少6 mm残留病变:曲线下面积0.817,以12 mm为界值灵敏度95%、特异度70.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the diagnostic performance of two-dimensional (2D) ultrasound parameters, three-dimensional (3D) power Doppler and contrast-enhanced indices in detecting residual disease in locally advanced cervical cancer patients triaged to neoadjuvant treatment followed by radical surgery. METHODS: Between October 2010 and June 2014, we screened 108 women with histologically documented locally advanced cervical cancer Stage IB2-IVA, of whom 88 were included in the final analysis. 2D ultrasound parameters, 3D power Doppler and contrast-ultrasound parameters were assessed 5 weeks after the end of neoadjuvant chemoradiation therapy. The pathological response was defined as complete (absence of any residual tumor after treatment) or partial (including microscopic and/or macroscopic residual tumor at pathology examination). The two response groups were compared and receiver-operating characteristics (ROC) curves generated to determine the best cut-off value of sonographic tumor diameter to predict residual disease. Histology was considered as reference. RESULTS: Complete pathological response to chemoradiation was observed in 40 (45.5%) patients and partial response in 48 (54.5%). The presence of residual disease, as confirmed at pathology examination, was detected by 2D grayscale ultrasound with a sensitivity of 64.6% and specificity of 65%. Color Doppler examination in the cases with lesions visualized on grayscale imaging detected the presence of residual disease, confirmed at pathology, with a sensitivity of 87.1% and specificity of 21.4%. The best area under the ROC curve (0.817) was for the detection of pathological residual disease of at least 6 mm in diameter, using a cut-off value of 12 mm for the largest tumor diameter assessed using 2D grayscale ultrasound (sensitivity, 95%; specificity, 70.6%). Neither 3D vascular indices nor contrast-ultrasound parameters obtained for lesions suspected at ultrasound following chemoradiation differed significantly between patients with histological complete and those with partial response. CONCLUSIONS: Our results show that grayscale and color Doppler ultrasound have a low level of diagnostic performance in detecting residual disease after neoadjuvant chemoradiation in patients with locally advanced cervical cancer. The best performance was achieved in detection of macroscopic (≥ 6 mm) residual disease. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Testa AC, Moro F, Pasciuto T, et al. PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery. Ultrasound Obstet Gynecol. 2018. PMID: 29119649. doi:10.1002/uog.18953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。